// Company Overview //
| Stock Name | 博安生物－Ｂ |
|---|---|
| Stock Code | 06955 |
| Company Full Name | 博安生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家綜合性生物制藥公司，致力于在中國及海外開發、制造及商業化不同治療領域的優質生物制品。 |
| Listing Date | 2022-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國山東省煙臺市高新技術產業開發區科技大道39號 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | https://www.boan-bio.com/cn/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2022-12-19 |
| Offer Price | HK$ 19.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 3,960 |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | 1,069,600 (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | —x |
| Valid Applications | — |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 21,178,080 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | -36.54 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 58,900,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 19.9 |
| First Day Change | -69.80% |
| First Day Volume | 1934930.0 |
| First Day Turnover | 38589400.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約59.5%或91.0百萬港元將用于核心產品的研發； 2、約31.4%或48.0百萬港元將用于我們管線中其他產品的研發； 3、約6.1%或9.3百萬港元將用于商業化目的； 4、約3.0%或4.6百萬港元將用于營運資金及其他一般企業用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
瑞银证券香港有限公司
安信融资(香港)有限公司
整体协调人 (2)
瑞银证券香港有限公司
安信国际证券(香港)有限公司
联席账簿管理人 (2)
瑞银证券香港有限公司
安信国际证券(香港)有限公司
联席牵头经办人 (5)
瑞银证券香港有限公司
安信国际证券(香港)有限公司
富途证券国际（香港）有限公司
利弗莫尔证券有限公司
元库证券有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 99,997,920 HKD | — | 47.22% | — | 6 months | 2023-06-30 |
| 2 | 傅和亮 | 23,118,480 HKD | — | 10.92% | — | 6 months | 2023-06-30 |
| 3 | 中国生物制药有限公司 | 27,244,800 HKD | — | 12.87% | — | 6 months | 2023-06-30 |
// Directors & Management //
| Chairman | 姜華 |
|---|---|
| Company Secretary | 黎少娟 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 山東綠葉制藥有限公司(70.81%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 200 | 1,266 | 555 | 0.44 |
| 400 | 233 | 204 | 0.88 |
| 600 | 52 | 16 | 1.31 |
| 800 | 30 | 22 | 1.73 |
| 1,000 | 57 | 9 | 2.16 |
| 1,200 | 12 | 7 | 2.58 |
| 1,400 | 15 | 15 | 3.00 |
| 1,600 | 8 | 3 | 3.38 |
| 1,800 | 9 | 6 | 3.67 |
| 2,000 | 72 | 5 | 4.07 |
| 3,000 | 17 | 1 | 6.06 |
| 4,000 | 10 | 10 | 8.00 |
| 5,000 | 22 | 22 | 10.00 |
| 6,000 | 8 | 8 | 12.00 |
| 7,000 | 3 | 3 | 14.00 |
| 8,000 | 1 | 1 | 16.00 |
| 9,000 | 1 | 1 | 18.00 |
| 10,000 | 43 | 43 | 19.00 |
| 20,000 | 2 | 2 | 38.00 |
| 30,000 | 1 | 1 | 55.99 |
| 40,000 | 2 | 2 | 74.00 |
| 50,000 | 2 | 2 | 90.00 |
| 80,000 | 1 | 1 | 137.00 |
| 184,950 | 1 | 1 | 924.75 |
| 250,000 | 1 | 1 | 428.00 |
Pool B (Large Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 300,000 | 1 | 1 | 1500.00 |
Allotment Benchmarks
